These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35986867)

  • 81. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke.
    Hoyer C; Filipov A; Neumaier-Probst E; Szabo K; Ebert A; Alonso A
    J Thromb Thrombolysis; 2018 May; 45(4):529-535. PubMed ID: 29476304
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation.
    Seelig J; Trinks-Roerdink EM; Chu G; Pisters R; Theunissen LJHJ; Trines SA; Pos L; Kirchhof CJHJ; de Jong SFAMS; den Hartog FR; van Alem AP; Polak PE; Tieleman RG; van der Voort PH; Lenderink T; Otten AM; de Jong JSSG; Gu YL; Luermans JGLM; Kruip MJHA; Timmer SAJ; de Vries TAC; Cate HT; Geersing GJ; Rutten FH; Huisman MV; Hemels MEW
    Eur Heart J Open; 2022 May; 2(3):oeac022. PubMed ID: 35919339
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation.
    Lin Y; Xiong H; Su J; Lin J; Zhou Q; Lin M; Zhao W; Peng F
    Heart Vessels; 2022 Jul; 37(7):1224-1231. PubMed ID: 35041061
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Aug; 72(2):105-112. PubMed ID: 29519547
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.
    Gorczyca I; Michalska A; Chrapek M; Jelonek O; Wałek P; Wożakowska-Kapłon B
    Cardiol J; 2021; 28(6):896-904. PubMed ID: 31313276
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Non-vitamin K antagonist oral anticoagulant use at doses inappropriately lower than recommended in outpatient older adults: a real-life data.
    Erdogan T; Erdogan O; Ozturk S; Oren MM; Karan MA; Bahat G
    Eur Geriatr Med; 2021 Aug; 12(4):809-816. PubMed ID: 33517553
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study.
    Miyazaki M; Matsuo K; Uchiyama M; Nakamura Y; Sakamoto Y; Misaki M; Tokura K; Jimi S; Okamura K; Adachi S; Yamamoto T; Shirai K; Urata H; Imakyure O
    J Pharm Health Care Sci; 2020; 6():2. PubMed ID: 32071730
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Lower Risk of Dementia in Patients With Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Population-Based Cohort Study.
    Hsu JY; Liu PP; Liu AB; Lin SM; Huang HK; Loh CH
    J Am Heart Assoc; 2021 Feb; 10(5):e016437. PubMed ID: 33586465
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 91. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
    Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Anticoagulant selection in relation to the SAMe-TT
    Ntaios G; Huisman MV; Diener HC; Halperin JL; Teutsch C; Marler S; Gurusamy VK; Thompson M; Lip GYH; Olshansky B;
    Hellenic J Cardiol; 2021; 62(2):152-157. PubMed ID: 33338644
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Consensus in cardiology on non-vitamin-K oral anticoagulants for patients with atrial fibrillation.
    Chueca Fernández E; López Granados A; Zuazola Martínez MDP; Del Castillo-Medina R
    Curr Med Res Opin; 2019 Sep; 35(9):1571-1582. PubMed ID: 30957564
    [No Abstract]   [Full Text] [Related]  

  • 96. Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients.
    Sheikh-Taha M; Deeb ME
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):195-201. PubMed ID: 30406915
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
    Tsai CT; Liao JN; Chen SJ; Jiang YR; Chen TJ; Chao TF
    Eur J Clin Invest; 2021 Jun; 51(6):e13488. PubMed ID: 33420738
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.